At a glance
- Originator Eisai Co Ltd
- Class Anti-ischaemics
- Mechanism of Action Antioxidants; Glutamate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cerebral ischaemia
Most Recent Events
- 19 Nov 1997 Discontinued-I for Cerebral ischaemia in Japan (Unknown route)